Cleveland Clinic's Breast Cancer Update: Review of Breast Cancer Symposia


 

2021 Update on HER2+ MBC: Neratinib/Cape vs. Lapatinib/Cape in MBC, New Oral Pan-HER TKIs, T-DXd, Trastuzumab Duocarmazine, Patritumab Deruxtecan, Margetuximab

194 views
March 5, 2021
1 Comment
Login to view comments. Click here to Login
2021